PL2852671T3 - Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna - Google Patents

Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna

Info

Publication number
PL2852671T3
PL2852671T3 PL13794196T PL13794196T PL2852671T3 PL 2852671 T3 PL2852671 T3 PL 2852671T3 PL 13794196 T PL13794196 T PL 13794196T PL 13794196 T PL13794196 T PL 13794196T PL 2852671 T3 PL2852671 T3 PL 2852671T3
Authority
PL
Poland
Prior art keywords
generation
ips cells
human ips
replicative rna
synthetic self
Prior art date
Application number
PL13794196T
Other languages
English (en)
Inventor
Steven F. Dowdy
Naohisa YOSHIOKA
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of PL2852671T3 publication Critical patent/PL2852671T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0696Artificially induced pluripotent stem cells, e.g. iPS
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4705Regulators; Modulating activity stimulating, promoting or activating activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • C12N9/127RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60Transcription factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60Transcription factors
    • C12N2501/602Sox-2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60Transcription factors
    • C12N2501/603Oct-3/4
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60Transcription factors
    • C12N2501/604Klf-4
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60Transcription factors
    • C12N2501/605Nanog
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60Transcription factors
    • C12N2501/606Transcription factors c-Myc
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
PL13794196T 2012-05-21 2013-05-21 Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna PL2852671T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261649876P 2012-05-21 2012-05-21
US201361798229P 2013-03-15 2013-03-15
EP13794196.9A EP2852671B1 (en) 2012-05-21 2013-05-21 Generation of human ips cells by a synthetic self- replicative rna
PCT/US2013/041980 WO2013177133A2 (en) 2012-05-21 2013-05-21 Generation of human ips cells by a synthetic self- replicative rna

Publications (1)

Publication Number Publication Date
PL2852671T3 true PL2852671T3 (pl) 2019-06-28

Family

ID=49624495

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13794196T PL2852671T3 (pl) 2012-05-21 2013-05-21 Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna

Country Status (14)

Country Link
US (4) US9862930B2 (pl)
EP (1) EP2852671B1 (pl)
JP (1) JP6396893B2 (pl)
CN (1) CN104508131B (pl)
AU (1) AU2013266496B2 (pl)
CA (1) CA2873964A1 (pl)
DK (1) DK2852671T3 (pl)
ES (1) ES2698527T3 (pl)
HU (1) HUE041853T2 (pl)
IL (2) IL235628B (pl)
PL (1) PL2852671T3 (pl)
PT (1) PT2852671T (pl)
SG (1) SG11201407595UA (pl)
WO (1) WO2013177133A2 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
SG11201804197RA (en) 2015-11-18 2018-06-28 Orbis Health Solutions Llc T7 alpha viral vector system
JPWO2018155620A1 (ja) * 2017-02-24 2020-01-09 剛士 田邊 神経系細胞の作製方法
JP7146211B2 (ja) * 2017-02-24 2022-10-04 剛士 田邊 人工多能性幹細胞の作製方法
CA3068917A1 (en) * 2017-07-05 2019-01-10 Wisconsin Alumni Research Foundation Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes
CN111094549A (zh) * 2017-09-13 2020-05-01 生物技术Rna制药有限公司 用于将体细胞重编程的rna复制子
US11229699B2 (en) 2017-11-06 2022-01-25 Intervet Inc. Feline calicivirus vaccine
EP3719133A4 (en) * 2017-11-30 2021-08-11 I Peace, Inc. METHOD FOR PRODUCING NERVOUS CELLS
KR102143320B1 (ko) 2018-08-28 2020-08-12 주식회사 스템랩 합성 메신저 rna를 이용하여 소변세포를 신경줄기세포로 직접 역분화하는 방법
MX2021004032A (es) * 2018-10-08 2021-07-06 Janssen Pharmaceuticals Inc Replicones basados en alfavirus para la administracion de bioterapeuticos.
WO2020146690A1 (en) * 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Methods for in vitro evolution of rna replicons
JP2022538847A (ja) * 2019-06-27 2022-09-06 イーエムディ・ミリポア・コーポレイション 不死化タンパク質を発現する自己複製性rnaベクターによる細胞増殖
KR20220129567A (ko) 2019-12-31 2022-09-23 엘릭서젠 쎄라퓨틱스, 인크. 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달
CN115484990A (zh) 2020-03-12 2022-12-16 基础科学研究院 诱导具有基因组序列变异的细胞凋亡的组合物及使用组合物诱导细胞凋亡的方法
WO2022050419A1 (ja) * 2020-09-04 2022-03-10 Heartseed株式会社 iPS細胞の品質改善剤、iPS細胞の製造方法、iPS細胞、及びiPS細胞製造用組成物
CN112458064A (zh) * 2020-11-20 2021-03-09 广西大学 盖他病毒全长感染性克隆、复制子***及其制备和应用
CN112852841A (zh) * 2021-02-03 2021-05-28 郑州大学 一种高效表达目的蛋白的顺式复制子rna构建体
WO2022204567A1 (en) 2021-03-25 2022-09-29 Bluerock Therapeutics Lp Methods for obtaining induced pluripotent stem cells
WO2022234268A1 (en) * 2021-05-04 2022-11-10 Mogrify Limited Cell conversion
US20230044997A1 (en) * 2021-07-15 2023-02-09 Turn Biotechnologies, Inc. Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
WO2023288285A1 (en) * 2021-07-15 2023-01-19 Turn Biotechnologies, Inc. Polycistronic expression vectors
US20230046606A1 (en) * 2021-07-15 2023-02-16 Turn Biotechnologies, Inc. Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use
CA3240645A1 (en) * 2021-12-20 2023-06-29 Melissa Carpenter Compositions and methods for cellular reprogramming using circular rna
TW202400252A (zh) 2022-04-28 2024-01-01 美商藍岩醫療公司 用於安全基因組整合之新位點及其使用方法
US20240082425A1 (en) 2022-06-23 2024-03-14 Turn Biotechnologies, Inc. Lipid structures and compositions comprising same
WO2024129743A2 (en) 2022-12-13 2024-06-20 Bluerock Therapeutics Lp Engineered type v rna programmable endonucleases and their uses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP1046421B8 (en) 1990-12-06 2006-01-11 Affymetrix, Inc. (a Delaware Corporation) Methods and reagents for very large scale immobilized polymer synthesis
ES2301178T3 (es) * 1996-04-05 2008-06-16 Novartis Vaccines & Diagnostic Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular.
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US20030232324A1 (en) 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
DE60233061D1 (de) 2001-09-06 2009-09-03 Alphavax Inc Alphavirus replikon-vektorsysteme
EP1386926A1 (en) 2002-07-29 2004-02-04 Bioxtal Methods for producing labelled recombinant polypeptides and uses thereof
US20050271639A1 (en) 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US7078218B2 (en) 2002-12-13 2006-07-18 Alphavax, Inc. Alphavirus particles and methods for preparation
CA2518546C (en) 2003-03-20 2012-11-13 Alphavax, Inc. Improved alphavirus replicons and helper constructs
US20060198854A1 (en) 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
WO2009067563A1 (en) 2007-11-19 2009-05-28 The Regents Of The University Of California Generation of pluripotent cells from fibroblasts
EP2072618A1 (en) * 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Use of RNA for reprogramming somatic cells
GB0801215D0 (en) * 2008-01-23 2008-02-27 Univ Sheffield Cell re-programming
JP2011516042A (ja) 2008-03-17 2011-05-26 へルムホルツ・ツェントルム・ミュンヘン−ドイチェス・フォルシュングスツェントルム・ヒューア・ゲズントハイト・ウント・ウムヴェルト(ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング) 部位特異的組み換えを用いて無ベクター誘導多能性幹(iPS)細胞を作製するベクターおよびその方法
US9497943B2 (en) * 2008-06-13 2016-11-22 Whitehead Institute For Biomedical Research Nucleic acid constructs encoding reprogramming factors linked by self-cleaving peptides
WO2010028019A2 (en) 2008-09-03 2010-03-11 The General Hospital Corporation Direct reprogramming of somatic cells using non-integrating vectors
EP2401372A4 (en) * 2009-02-27 2012-09-19 Univ Kyoto NEW NUCLEAR REPROGRAMMING SUBSTANCE
WO2010118244A1 (en) 2009-04-08 2010-10-14 Alphavax, Inc. Alphavirus Replicon Particles Expressing TRP2
US8609417B2 (en) 2009-04-13 2013-12-17 The Regents Of The University Of California Methods and compositions for stem cell cultures
WO2011109612A2 (en) * 2010-03-03 2011-09-09 The General Hospital Corporation Method for selecting an ips cell
CA2796464C (en) * 2010-04-16 2021-08-03 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
TR201809547T4 (tr) 2012-11-09 2018-07-23 Biontech Rna Pharmaceuticals Gmbh Hücresel RNA ifadesine yönelik yöntem.

Also Published As

Publication number Publication date
CA2873964A1 (en) 2013-11-28
WO2013177133A3 (en) 2014-03-20
CN104508131B (zh) 2018-11-23
AU2013266496A1 (en) 2014-11-27
US20210108179A1 (en) 2021-04-15
EP2852671A4 (en) 2015-12-23
SG11201407595UA (en) 2014-12-30
EP2852671B1 (en) 2018-08-22
PT2852671T (pt) 2018-11-29
JP2015519898A (ja) 2015-07-16
WO2013177133A2 (en) 2013-11-28
US20190338252A1 (en) 2019-11-07
IL272917A (en) 2020-04-30
JP6396893B2 (ja) 2018-09-26
ES2698527T3 (es) 2019-02-05
US10370646B2 (en) 2019-08-06
EP2852671A2 (en) 2015-04-01
US20180216079A1 (en) 2018-08-02
AU2013266496B2 (en) 2018-08-09
HUE041853T2 (hu) 2019-05-28
US10793833B2 (en) 2020-10-06
DK2852671T3 (en) 2018-12-10
CN104508131A (zh) 2015-04-08
IL235628A0 (en) 2015-01-29
IL235628B (en) 2020-03-31
US20150159143A1 (en) 2015-06-11
US9862930B2 (en) 2018-01-09

Similar Documents

Publication Publication Date Title
IL272917A (en) Generation of human induced pluripotent stem cells using artificial self-replicating RNA
HK1212388A1 (en) Methods of tissue generation
HK1212261A1 (en) Methods of tissue generation
SG11201501729TA (en) Three-dimensional cell culturing
PL2741535T3 (pl) Sposób prowadzenia umieszczania nowych małych komórek
EP2815546A4 (en) CONSTRUCTION OF A LARGE SCALE DVPN
EP2764325A4 (en) USE OF A VIDEOGRAMMETRY FOR THE MANUFACTURE OF PARTS
GB201222882D0 (en) Ultrasound generation
EP2790628A4 (en) DIAPER
EP2667383A4 (en) PRESSURE WATER REACTOR
GB2489486B (en) Improvements relating to construction
EP2831741A4 (en) PREPARATION OF A TEST CENTERED MODEL OF ONE APPLICATION
EP2814944A4 (en) BIOMASS YIELD GENES
ZA201205924B (en) Reactor
EP2793379A4 (en) GENERATOR
BR112013028889A2 (pt) recheio de reator
GB2493964B (en) Cultivator
GB201104001D0 (en) Improvements to goggles
ZA201402237B (en) Generator
EP2809685A4 (en) ELECTROCHEMICAL SYNTHESIS OF CHLORO-CHITOSAN
GB201203038D0 (en) Waveform generation
EP2736056A4 (en) REACTOR
EP2700402A4 (en) NEW USES OF LICOCHALCONE A
CO6811845A2 (es) Reactor de recuperación
GB2507762B (en) Improvements to dartboards